Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies

Next Previous
Search
Trial Profile

A Phase I Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peritoneal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Jun 2023 Results of 7 studies (NCT00666991, NCT03636256, NCT03077659, NCT04221828, NCT03029585, NCT03077685, NCT04314895) assessing safety findings in subjects co-administered LSAM-PTX or LSAM-DTX and common SOC therapies for treatment of carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 22 May 2013 Planned end date changed from 1 Aug 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 22 May 2013 Planned end date changed from 1 Aug 2015 to 1 May 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top